Promazine Hydrochloride
FDA-approved product (tablet, oral), marketed as Promazine Hydrochloride, Sparine.
- Registered studies
- 0
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Psychosis
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Phenothiazines with aliphatic side-chain
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA19.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli19.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae10.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis67.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Promazine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- NitisinoneExisting use: Tyrosinemia59.6% AI-predicted activityagainst M. tuberculosis17 registered studies
- Tenapanor HydrochlorideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome59.6% AI-predicted activityagainst M. tuberculosis2 registered studies
- Edoxaban TosylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 3 more59.5% AI-predicted activityagainst M. tuberculosis22 registered studies
- AprocitentanExisting use: Hypertension59.5% AI-predicted activityagainst M. tuberculosis14 registered studies
- PlecanatideExisting use: Constipation59.5% AI-predicted activityagainst M. tuberculosis15 registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more59.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- VemurafenibExisting use: Cancer, Cutaneous melanoma, Melanoma and 2 more59.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- IrbesartanExisting use: Cardiovascular disease, Chronic kidney disease, Chronic renal failure syndrome and 3 more59.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Dihydroergotamine MesylateExisting use: Migraine disorder59.4% AI-predicted activityagainst M. tuberculosis21 registered studies
- HalazepamExisting use: Anxiety59.4% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NisoldipineExisting use: Cardiovascular disease, Hypertension59.4% AI-predicted activityagainst M. tuberculosis6 registered studies
- Primaquine PhosphateExisting use: Malaria59.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.